Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 00:16 | 2026-03-05 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $146.03 | 10,699 | $1,562,328 | 301,185 |
| 2026-03-06 00:35 | 2026-03-04 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | OPT+S | $489.42 | 2,000 | $978,839 | 8,480 |
| 2026-03-06 00:34 | 2026-03-04 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $490.17 | 20 | $9,803 | 4,190 |
| 2026-03-06 00:36 | 2026-03-04 | UTHR | UNITED THERAPEUTICS Corp | KURZWEIL RAY | Director | OPT+S | $489.02 | 4,910 | $2,401,088 | 12,670 |
| 2026-03-06 00:33 | 2026-03-03 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $499.42 | 9,500 | $4,744,466 | 130 |
| 2026-03-06 04:00 | 2026-03-03 | OLMA | Olema Pharmaceuticals, Inc. | Mitchell Shawnte | Officer | OPT+S | $23.79 | 40,000 | $951,504 | 0 |
| 2026-03-06 03:06 | 2026-03-03 | BCAX | Bicara Therapeutics Inc. | Raben David | Officer | OPT+S | $18.52 | 16,500 | $305,610 | 55,286 |
| 2026-03-06 03:08 | 2026-03-03 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.22 | 16,518 | $300,971 | 145,355 |
| 2026-03-06 03:10 | 2026-03-03 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $18.16 | 17,392 | $315,893 | 205,141 |
| 2026-03-06 02:55 | 2026-03-03 | ANTX | AN2 Therapeutics, Inc. | Williams Sarah Joanne | Officer | SELL | $1.06 | 327 | $347 | 66,848 |
| 2026-03-06 02:55 | 2026-03-04 | AKBA | Akebia Therapeutics Inc. | Butler John P. | Director, Officer | BUY | $1.25 | 69,270 | $86,588 | 3,367,064 |
| 2026-03-06 02:13 | 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $79.74 | 6,659 | $530,987 | 4,347 |
| 2026-03-06 02:13 | 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | OPT+S | $79.23 | 85,089 | $6,741,670 | 80,554 |
| 2026-03-06 02:14 | 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $79.40 | 20,106 | $1,596,432 | 22,541 |
| 2026-03-06 02:14 | 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | Diaz Allene M. | Director | OPT+S | $79.35 | 54,878 | $4,354,427 | 3,811 |
| 2026-03-06 02:14 | 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | OPT+S | $79.51 | 21,332 | $1,696,182 | 11,014 |
| 2026-03-06 02:14 | 2026-03-03 | IONS | IONIS PHARMACEUTICALS INC | LOSCALZO JOSEPH | Director | OPT+S | $80.26 | 1,032 | $82,833 | 36,330 |
| 2026-03-06 01:46 | 2026-03-05 | ANIP | Ani Pharmaceuticals Inc. | CAREY STEPHEN P. | Officer | OPT+S | $75.50 | 7,312 | $552,031 | 185,543 |
| 2026-03-06 00:36 | 2026-03-04 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $317.97 | 19,000 | $6,041,413 | 130 |
| 2026-03-06 00:37 | 2026-03-05 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $483.16 | 8,300 | $4,010,187 | 36,844 |
| 2026-03-06 00:27 | 2026-03-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $61.87 | 26,000 | $1,608,729 | 50,440 |
| 2026-03-06 00:29 | 2026-03-03 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dreyer Scott | Officer | SELL | $40.41 | 49,976 | $2,019,435 | 71,770 |
| 2026-03-05 19:05 | 2026-03-03 | LGND | LIGAND PHARMACEUTICALS INC | Sabba Stephen L | Director | OPT+S | $201.50 | 2,034 | $409,851 | 33,793 |
| 2026-03-05 16:00 | 2026-03-04 | FBLG | FibroBiologics, Inc. | Khoja Hamid | Officer | BUY | $0.38 | 30,000 | $11,400 | 61,250 |
| 2026-03-05 00:21 | 2026-03-02 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer | SELL | $495.96 | 892 | $442,396 | 22,811 |
| 2026-03-05 00:16 | 2026-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $25.65 | 10,000 | $256,518 | 49,744 |
| 2026-03-05 00:00 | 2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Klee Justin B. | Director, Officer | SELL | $14.47 | 29,282 | $423,760 | 3,334,616 |
| 2026-03-05 00:00 | 2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Cohen Joshua B | Director, Officer | SELL | $14.48 | 29,282 | $424,120 | 3,334,683 |
| 2026-03-05 00:00 | 2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Mazzariello Gina | Officer | SELL | $14.52 | 6,844 | $99,378 | 134,430 |
| 2026-03-05 00:30 | 2026-03-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Smethurst Dominic | Officer | SELL | $8.30 | 6,097 | $50,601 | 89,790 |
| 2026-03-05 00:36 | 2026-03-02 | QURE | uniQure N.V. | KLEMT CHRISTIAN | Officer | SELL | $9.95 | 12,532 | $124,693 | 198,981 |
| 2026-03-05 00:31 | 2026-03-02 | QURE | uniQure N.V. | Potts Jeannette | Officer | SELL | $9.95 | 8,578 | $85,351 | 106,495 |
| 2026-03-05 01:01 | 2026-03-03 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | Director, Officer, 10% owner | BUY | $3.63 | 10,000 | $36,300 | 382,702 |
| 2026-03-05 00:30 | 2026-03-02 | ANNX | Annexon, Inc. | ARTIS DEAN RICHARD | Officer | SELL | $5.43 | 5,894 | $32,004 | 180,093 |
| 2026-03-05 00:30 | 2026-03-02 | ANNX | Annexon, Inc. | Yednock Ted | Officer | SELL | $5.42 | 5,566 | $30,168 | 154,161 |
| 2026-03-05 00:30 | 2026-03-02 | ANNX | Annexon, Inc. | Overdorf Michael | Officer | SELL | $5.42 | 4,339 | $23,517 | 182,625 |
| 2026-03-05 00:30 | 2026-03-02 | ANNX | Annexon, Inc. | Dananberg Jamie | Officer | SELL | $5.43 | 5,820 | $31,603 | 123,582 |
| 2026-03-05 00:30 | 2026-03-02 | ANNX | Annexon, Inc. | Lew Jennifer | Officer | SELL | $5.42 | 5,565 | $30,162 | 170,700 |
| 2026-03-05 00:17 | 2026-03-02 | ARQT | Arcutis Biotherapeutics Inc. | Leonard Keith R | Director | OPT+S | $25.39 | 39,272 | $997,195 | 22,123 |
| 2026-03-05 00:00 | 2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Bedrosian Camille L | Officer | SELL | $14.58 | 6,461 | $94,205 | 169,295 |
| 2026-03-05 00:00 | 2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | FRATES JAMES M | Officer | SELL | $14.52 | 7,909 | $114,851 | 165,638 |
| 2026-03-05 05:04 | 2026-03-02 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $200.50 | 467 | $93,632 | 42,720 |
| 2026-03-05 04:15 | 2026-03-02 | ALKS | Alkermes plc. | Gaffin David Joseph | Officer | SELL | $29.53 | 4,068 | $120,108 | 235,626 |
| 2026-03-05 04:16 | 2026-03-02 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $29.72 | 9,000 | $267,485 | 89,389 |
| 2026-03-05 04:18 | 2026-03-02 | ALKS | Alkermes plc. | Nichols Christian Todd | Officer | SELL | $30.00 | 6,000 | $180,000 | 109,769 |
| 2026-03-05 04:19 | 2026-03-02 | ALKS | Alkermes plc. | Parisi Samuel Joseph | Officer | SELL | $29.29 | 6,890 | $201,808 | 7,717 |
| 2026-03-05 03:54 | 2026-03-02 | FOLD | AMICUS THERAPEUTICS, INC. | Campbell Bradley L | Director, Officer | SELL | $14.35 | 22,500 | $322,839 | 998,680 |
| 2026-03-05 03:30 | 2026-03-02 | ALNY | Alnylam Pharmaceuticals Inc. | Tanguler Tolga | Officer | SELL | $327.65 | 1,598 | $523,584 | 36,606 |
| 2026-03-05 03:30 | 2026-03-02 | ALNY | Alnylam Pharmaceuticals Inc. | Fitzgerald Kevin Joseph | Officer | SELL | $323.62 | 3,250 | $1,051,773 | 21,860 |
| 2026-03-05 03:31 | 2026-03-02 | ALNY | Alnylam Pharmaceuticals Inc. | Garg Pushkal | Officer | SELL | $323.63 | 3,492 | $1,130,131 | 23,406 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.